Skip to main content
. 2016 Aug 29;1(5):386–398. doi: 10.1016/j.jacbts.2016.05.008

Figure 1.

Figure 1

The Need for More Effective Methods of Nonclinical Screening in Cancer Treatment-Related Cardiotoxicities

There are numerous in vivo, in vitro, and in silico models that can be used for both nonclinical testing of CV toxicities and follow-up investigations of underlying mechanisms, which can be used to develop cardioprotective therapies. IND = investigational new drug; NDA = new drug application.